Progress on the Discovery of Inhibitors of InhA, the FAS II Enoyl-ACP Reductase TB Drug Discovery Targeted on InhA

Title:Progress on the Discovery of Inhibitors of InhA, the FAS II Enoyl-ACP Reductase TB Drug Discovery Targeted on InhA

Volume: 13 Issue: 6

Author(s): Yi Zhang, Longxiang Xie and Jianping Xie

Affiliation:

Keywords: Drug discovery, drug resistance, enoyl-ACP reductase, InhA, isoniazid, tuberculosis.

Abstract: With ever-increasing drug resistant clinical isolates, novel antibiotics with new targets are urgently needed. Tuberculosis, caused by Mycobacterium tuberculosis, showed formidable antibiotics resistance. InhA, the enoyl-acyl carrier protein (ACP) reductase involved in the type II fatty acid synthesis pathway (FASII) in Mycobacterium tuberculosis, represents an appealing target for the development of new anti-tuberculosis (TB) agents. Inhibitors against InhA might be ideal lead or antibiotics. The latest development of InhA inhibitors is summarized in this paper.

Cite this article as:

Zhang Yi, Xie Longxiang and Xie Jianping, Progress on the Discovery of Inhibitors of InhA, the FAS II Enoyl-ACP Reductase TB Drug Discovery Targeted on InhA, Letters in Drug Design & Discovery 2016; 13 (6) . https://dx.doi.org/10.2174/1570180812666151016205422